Australian Budget Gives On Biotech, Takes It Easier Than Expected On Reimbursement
This article was originally published in PharmAsia News
Executive Summary
The first budget by Australia’s Liberal Party-led coalition that came to power in September last year brought a surprise budget boost for biotech spending, but also delivered in part on promises to curb reimbursement spending.
You may also be interested in...
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.
INTERVIEW: Business Is Personal For Avita CEO Kelliher
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.
INTERVIEW: Business Is Personal For Avita CEO Kelliher
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.